INTERIM RESULTS OF A PHASE II STUDY OF FONDAZIONE ITALIANA LINFOMI ON GEMCITABINE PLUS ROMIDEPSIN IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA PATIENTS

被引：0
|
作者：
Pellegrini, C. [1 ]
Broccoli, A. [1 ]
Casadei, B. [1 ]
Chiappella, A. [2 ]
Corradini, P. [3 ]
Derenzini, E. [1 ]
Dodero, A. [3 ]
Farina, L. [3 ]
Gandolfi, L. [1 ]
Ladetto, M. [4 ]
Monaco, F. [4 ]
Orsucci, L. [2 ]
Quirini, F. [1 ]
Salvi, F. [4 ]
Spina, F. [3 ]
Stefoni, V. [1 ]
Tonialini, L. [1 ]
Vitolo, U. [2 ]
Argnani, L. [1 ]
Cavo, M. [1 ]
Zinzani, P. L. [1 ]
机构：
[1] Univ Bologna, Inst Hematol L & A Seragnoli, Bologna, Italy
[2] Azienda Osped Univ Citta Salute & Sci Torino, Hematol, Turin, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Hematol, Milan, Italy
[4] SS Antonio & Biagio Hosp Alessandria, Hematol, Alessandria, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C029
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [31] Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).
    Piekarz, Richard
    Wright, John
    Frye, Robin
    Allen, Steven L.
    Joske, David
    Kirschbaum, Mark
    Lewis, Ian D.
    Prince, Miles
    Smith, Sonali
    Jaffe, Elaine S.
    Bates, Susan
    BLOOD, 2009, 114 (22) : 661 - 662
  • [32] Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis
    Wesson, Emily
    Ruben, Charnelle
    Horowitz, Sandra B.
    Woolery, Joseph
    Feng, Lei
    Garg, Naveen
    Ahmed, Sairah
    Khouri, Issa F.
    Fanale, Michelle A.
    BLOOD, 2014, 124 (21)
  • [33] Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study
    Vu, Khoan
    Wu, Chi-Heng
    Yang, Chen-Yen
    Zhan, Aaron
    Cavallone, Erika
    Berry, Wade
    Heeter, Pamela
    Pincus, Laura
    Wieduwilt, Matthew J.
    William, Basem M.
    Andreadis, Charalambos
    Kaplan, Lawrence K.
    McCormick, Frank
    Porcu, Pierluigi
    Brammer, Jonathan E.
    Ai, Weiyun Z.
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 1000 - 1008
  • [34] Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)
    Anastasia, Antonella
    Carlo-Stella, Carmelo
    Corradini, Paolo
    Salvi, Flavia
    Rusconi, Chiara
    Pulsoni, Alessandro
    Hohaus, Stefan
    Pregno, Patrizia
    Viviani, Simonetta
    Brusamolino, Ercole
    Luminari, Stefano
    Giordano, Laura
    Santoro, Armando
    BLOOD, 2012, 120 (21)
  • [35] Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL)
    Horwitz, S. M.
    Coiffier, B.
    Foss, F. M.
    Prince, H. M.
    Sokol, L.
    Greenwood, M.
    Caballero, D.
    Borchmann, P.
    Morschhauser, F.
    Wilhelm, M.
    Pinter-Brown, L. C.
    Padmanabhan, S.
    Shustov, A. R.
    Nichols, J.
    Balser, J.
    Carroll, S.
    Pro, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
    Coiffier, Bertrand
    Pro, Barbara
    Prince, H. Miles
    Foss, Francine
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Borchmann, Peter
    Morschhauser, Franck
    Wilhelm, Martin
    Pinter-Brown, Lauren
    Padmanabhan, Swaminathan
    Shustov, Andrei
    Nichols, Jean
    Carroll, Susan
    Balser, John
    Balser, Barbara
    Horwitz, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 631 - 636
  • [37] Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
    Kim, Won-Seog
    Fukuhara, Noriko
    Yoon, Dok-Hyun
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Negoro, Eiju
    Izutsu, Koji
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Kang, Hye Jin
    Ko, Po-Shen
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Tobinai, Kensei
    BLOOD ADVANCES, 2023, 7 (17) : 4903 - 4912
  • [38] Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T- Cell Lymphoma
    Fukuhara, Noriko
    Kim, Won Seog
    Yoon, Dok Hyun
    Negoro, Eiju
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Izutsu, Koji
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Kang, Hye Jin
    Ko, Po-Shen
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Tobinai, Kensei
    BLOOD, 2021, 138
  • [39] Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Maeda, Yoshinobu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (10): : 2061 - 2068
  • [40] Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis
    Iyer, Swaminathan
    Prakash, Rishab
    Feng, Lei
    Agbedia, Owhofasa
    Xu, Jie
    Lee, Hun Ju
    Malpica, Luis
    Ahmed, Sairah
    Oki, Yasuhiro
    Chihara, Dai
    Peyton, Karen
    Steiner, Raphael
    Nastoupil, Loretta
    Fayad, Luis
    Vega, Francisco
    Flowers, Christopher
    Neelapu, Sattva
    Nair, Ranjit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S468 - S469
12345